Core Viewpoint - Betaini, once known as the "cosmetic medicine leader," faces its most severe challenge since its listing in Q1 2025, with a significant decline in revenue and profit [1][2] Financial Performance - The company's revenue for the period was 949 million yuan, a year-on-year decrease of 13.51% [1] - The net profit attributable to shareholders was only 28.34 million yuan, down 83.97% year-on-year [1] - Operating cash flow was negative, reaching -68.65 million yuan in Q1 [2] Brand and Market Position - The core brand, Winona, is experiencing a slowdown in growth and a weakening market position, which poses the biggest risk to Betaini [1] - Winona's ranking in the beauty category on Tmall dropped from 5th to 9th during the 2023 Double 11 shopping festival [1] - The company has invested 536 million yuan in acquiring brands like Jirui and Bomei, but these new businesses have not effectively supported the company's performance [1] Industry Challenges - The competitive landscape in the efficacy skincare sector has intensified, leading to increased pressure on Betaini [1] - The company's reliance on online channels is showing signs of fatigue, with offline channels also facing challenges due to reduced foot traffic [1] - The current business model of "heavy marketing and light R&D" is proving to be limited, necessitating a shift towards innovation and product strength [2]

Core Viewpoint - Proya has reported strong financial performance with 2024 revenue exceeding 10 billion yuan for the first time, reaching 10.778 billion yuan, and a net profit growth of 30% year-on-year [1][2] Financial Performance - In Q1 2025, Proya achieved revenue of 2.36 billion yuan, representing an 8.1% year-on-year increase, with a net profit of 390 million yuan [1] - The 2024 revenue of Proya was 8.581 billion yuan, showing a year-on-year growth of 19.55% [2] - The main brand Proya generated 8.58 billion yuan in revenue, accounting for 79.7% of total revenue, with a year-on-year growth of 19.6% [3] Management Changes - The management transition marked a strategic shift for the company, with co-founder Fang Yu-you stepping down as general manager, succeeded by his nephew Hou Ya-meng [2] - Despite the leadership change, Proya aims to establish itself among the top ten global cosmetics companies in the next decade [2] Brand and Product Development - Proya has diversified its brand portfolio, including popular skincare and makeup brands, with significant growth in sub-brands like Off&Relax and Cai Tang [3] - The company has accelerated product launches in 2025, introducing several new products within five months [5] Sales and Marketing Strategy - Proya's online sales reached 10.234 billion yuan, accounting for 95.06% of total revenue, while offline sales decreased by 13.63% to 532 million yuan [3] - The company has invested heavily in marketing, with sales expenses amounting to 5.161 billion yuan, representing 47.88% of revenue, and an increase of 29.93% year-on-year [4] Research and Development - Proya has established R&D centers in multiple locations and formed a joint venture for core anti-aging ingredients, although R&D expenses remain below 2% of revenue [5]

Core Insights - The medical aesthetics industry is experiencing significant revenue declines among major players, indicating a painful transformation phase for traditional companies [1][2][5] - Huaxi Biological, Aimeike, and Haohai Biological show varying degrees of revenue decline, highlighting differences in business structure and strategic deployment [1][2] - The industry is facing fundamental changes, raising concerns about which companies may fall behind in this transformation [1][8] Company Performance - Huaxi Biological reported a 20.77% year-on-year revenue decline in Q1 2025, with revenue shrinking to 1.078 billion yuan [1] - Aimeike's revenue decreased by 17.90% to 663 million yuan, while Haohai Biological's revenue fell by 4.25% to 619 million yuan [1] - Huaxi Biological's net profit plummeted from 961 million yuan in 2022 to 174 million yuan in 2024, with a further 58.13% decline in Q1 2025 [2][4] Strategic Adjustments - Huaxi Biological is undergoing a significant management overhaul, with leadership changes aimed at addressing operational challenges and improving performance [3][4] - The company is focusing on new fields such as glycoscience and cell biology, which has led to increased management costs [2][3] - Aimeike is shifting its strategy to accelerate product updates and pursue acquisitions in new areas like botulinum toxin and semaglutide [5][6] Market Dynamics - The medical aesthetics market is witnessing intense competition, particularly in the hyaluronic acid segment, raising concerns about whether the market has peaked [8][9] - New materials like hydroxyapatite and recombinant collagen are emerging as potential competitors to hyaluronic acid, indicating a shift in market dynamics [8][9] - Regulatory challenges and lengthy approval processes for medical products are significant barriers to industry growth, impacting companies' ability to innovate [9][10] Future Outlook - Huaxi Biological's turnaround efforts may take time to yield results, especially given its high marketing expenditures [10] - Aimeike's success will depend on the speed of product approvals and market acceptance of its diversified product strategy [6][10] - Haohai Biological is exploring new materials to drive growth, but its performance is still affected by pricing pressures from centralized procurement policies [7][10]

Group 1 - The Hong Kong stock market rebounded last week amid the easing of tensions from the Trump tariff war, but market sentiment remains cautious due to numerous uncertainties [1] - Major tech companies in the US, including Apple, Microsoft, Amazon, and Meta, are set to release their earnings reports this week, with a focus on performance and supply chain conditions [2] - The upcoming May Day holiday may set the tone for market trends, with technology and domestic demand stimulation expected to be key focus areas [3] Group 2 - The Chinese government has approved nuclear power projects, including the Zhejiang Sanmen Phase III project, indicating ongoing investment in nuclear energy [4] - The surgical robot company MicroPort has seen significant growth potential, with domestic installations expected to accelerate due to regulatory changes and increased clinical recognition [5] - The collaboration between Honghu and MicroPort in overseas markets is anticipated to enhance growth, with a notable increase in their transaction limits for related business [6] Group 3 - The personal care sector is experiencing significant growth driven by product innovation and new distribution channels, with companies like Ruyuchen and Dengkang Oral achieving substantial revenue increases [7] - The beauty sector is also thriving, with companies like Jizi Biotechnology and Marumi Biotech reporting impressive revenue growth, indicating a shift in consumer preferences towards innovative products [7] - The medical aesthetics market is witnessing new opportunities with the approval of new products, suggesting a robust growth trajectory for companies in this space [7] Group 4 - The Hong Kong stock market is advised to focus on companies like Maogeping and Juzibio, which are positioned for growth in their respective sectors [8] - The Hang Seng Index is currently stable, with a significant number of open contracts indicating a cautious outlook amid external uncertainties [9] - Analysts remain optimistic about the relative performance of Hong Kong stocks, particularly in sectors sensitive to tariffs and those benefiting from domestic demand policies [12]

特别申明： 点击注册小程序 查看完整报告 一季度公司原料及医疗终端业务收入保持增长，生物活性物原料和医疗终端新管线研发、注册和市场化进 度加快，但皮肤科学创新及转化业务依然处于调整周期，拖累整体业绩表现。 毛利率同比小幅下滑，管理变革+长期战略性投入，期间费用率同比有所升高：1Q2025，公司毛利率为 72.2%，同比-3.6pcts；公司归母净利率为9.5%，同比-8.4pcts。 1Q2025，公司期间费用率为58.4%，同比+7.1pcts，其中销售、管理、研发和财务费用率分别为： 36.6%/12.5%/9.7%/-0.4%，分别同比+0.5/+4.0/+2.7 /-0.1pcts。我们认为管理费用率升高的主要原因系管理 变革以及长期战略性产能布局导致相关费用增加。 本订阅号中所涉及的证券研究信息由光大证券研究所编写，仅面向光大证券专业投资者客户，用作新媒体形势下研究 信息和研究观点的沟通交流。非光大证券专业投资者客户，请勿订阅、接收或使用本订阅号中的任何信息。本订阅号 难以设置访问权限，若给您造成不便，敬请谅解。光大证券研究所不会因关注、收到或阅读本订阅号推送内容而视相 关人员为光大证券的客户。 报 ...

点击注册小程序 查看完整报告 特别申明： 本订阅号中所涉及的证券研究信息由光大证券研究所编写，仅面向光大证券专业投资者客户，用作新媒体形势下研究 信息和研究观点的沟通交流。非光大证券专业投资者客户，请勿订阅、接收或使用本订阅号中的任何信息。本订阅号 难以设置访问权限，若给您造成不便，敬请谅解。光大证券研究所不会因关注、收到或阅读本订阅号推送内容而视相 关人员为光大证券的客户。 今 日 聚 焦 【电新】上海车展趋势观察：大电量增程、商用车电动化、宁德时代引领新技术——碳中和领域动态追踪（一 百五十五） 宁德时代引领新技术突破，骁遥双核+自生成锂/钠负极再次拉开产品代差。增程车型有望成为电动化下半 场主力，大电量增程成为趋势。重卡等商用车电动化加速。上海车展新车型发布，大电量增程、商用车电 动化等趋势有望带动锂电需求，新技术突破有望催化固态电池、钠电等主题行情。 （殷中枢/陈无忌） 2025-04-27 您可点击今日推送内容的第1条查看 【汽车】2025上海车展开幕，聚焦智能化主旋律——汽车和汽车零部件板块跟踪报告 2025上海车展开幕，智驾+机器人共振，全产业链变革加速。1）预计2025E销量提振前景依然可期， ...

Industry Overview - The cosmetics industry is undergoing a significant transformation due to slowing consumer recovery and intensified competition, leading to a deep adjustment period driven by evolving consumer demands and channel model changes [1] - Domestic brands are reshaping market dynamics, with market share projected to reach 55.2% by 2024, an increase of 23% since 2020 [1] - There is a surge in demand for efficacy-driven products, particularly in skincare, with strong interest in anti-aging and whitening products [1] - Emerging technologies such as plant-based ingredients and scientific anti-aging solutions are becoming core competitive advantages [1] - The integration of domestic and international channels is redefining value pathways in the industry [1] Company Performance - Betaini has demonstrated resilience against industry pressures, achieving a revenue of 5.736 billion yuan in 2024, a year-on-year growth of approximately 3.87%, and a net profit of 503 million yuan [3] - The company has maintained positive operating cash flow for three consecutive years, with a year-on-year increase of 13.83% in 2024, highlighting its financial robustness [3] - Betaini's gross profit margin reached 73.74% in 2024, indicating effective cost management and a focus on high-value products [3] Shareholder Value - Over the past four years, Betaini has distributed 1.098 billion yuan in cash dividends to shareholders, with a dividend payout ratio of 50.25% in 2024, significantly higher than the industry average of 30% [4] - The company has also announced a share buyback plan of 235 million yuan for 2024, reinforcing its commitment to returning value to shareholders [4] Innovation and R&D - Betaini's R&D investment reached 337 million yuan in 2024, accounting for 5.87% of its revenue, positioning it as a leader in R&D intensity within the industry [5] - The company has established a plant extraction laboratory in Yunnan, successfully developing 13 unique plant ingredients, enhancing its product competitiveness [8] - Betaini's global R&D collaboration model, linking its Yunnan lab with a Swiss anti-aging research center, strengthens its position in the efficacy skincare market [10] Market Strategy - Betaini has built a multi-brand ecosystem through "internal incubation and external mergers," covering diverse skin needs and fostering collaborative growth [13] - The company has strategically invested in high-end body care brands to enhance its efficacy skincare ecosystem, aiming to establish a first-mover advantage in this segment [16] - Betaini is leveraging OMO (Online-Merge-Offline) retail strategies and expanding into Southeast Asia, enhancing its market presence and growth potential [17][19] Consumer Trends - Recent data indicates that product ingredients and efficacy are the primary concerns for Chinese consumers when purchasing cosmetics, aligning with national policies promoting the development of unique plant-based ingredients [7] - The cosmetics retail market in China has shown signs of recovery, with a total retail sales of 72 billion yuan in January-February 2024, reflecting a 4.4% year-on-year growth [22] Future Outlook - Betaini is positioned to benefit from the dual advantages of the "Healthy China" strategy and consumer upgrades, potentially leading to a reassessment of its technological and ecological value in the capital market [25]

以下文章来源于财经天下WEEKLY ，作者财经天下 财经天下WEEKLY . 《财经天下》周刊官方账号，提供有品质的深度报道，讲述中国企业在时代浪潮中的精彩故事。 毛利率在80%以上，研发投入却较低。 作者：林木 编辑：吴跃 来源：财经天下WEEKLY 因为陷入"EGF（表皮生长因子）罗生门"，可复美近期被推上风口浪尖。 不久前，有消费者反映可复美产品"违规添加EGF"。随后可复美母公司巨子生物予以否认， 称"旗下所有产品均未添加"。伴随着舆论发酵，社媒平台上，看客们吵得沸沸扬扬，力挺声、 质疑声四起，也让"可复美"这个名字被更多人知晓。 做过医美或者皮肤敏感的消费者，大多对"可复美"三个字不陌生。这个主打皮肤修复的品牌， 早年间主要深耕院线渠道，之后乘上直播电商风口，进入更多人视野，撬开更多钱包。过去6 年，其母公司巨子生物营收从9.57亿元涨至55.39亿元，翻了5倍多。 2024年，巨子生物一举超越珀莱雅，成为市值最高的国货美妆公司，此后一直保持至今。公 司创始人，现年59岁的陕西人范代娣，也因此登顶国货美妆首富。 爱美的女生，这些年托举过不少美妆公司。当下风头最盛的可复美和巨子生物，到底是何来 头？为 ...

Core Viewpoint - The domestic market competition for hyaluronic acid injection products is intensifying, with Huaxi Biological's new product "Bobo" being the first hyaluronic acid injection containing lidocaine approved for sale in China, aimed at improving user experience by reducing pain during injection [1][2]. Group 1: Product Launch and Market Position - Huaxi Biological's "Bobo" is composed of 15mg/ml hyaluronic acid and 3mg/ml lidocaine, designed to enhance treatment experience by minimizing pain [1]. - The product's pricing is yet to be determined, and its market performance remains uncertain due to the presence of numerous existing competitors in the market [3]. - "Bobo" is the 10th medical beauty injection product from Huaxi Biological, following several successful launches in the hyaluronic acid category [4]. Group 2: Financial Performance and Future Outlook - In 2024, Huaxi Biological's skincare business is expected to face challenges, but the medical beauty segment is showing steady growth, with projected revenue of 1.44 billion yuan, a year-on-year increase of 32.03% [5]. - The revenue from the micro-crosslinked "Renzhi® Doll Needle" has more than doubled year-on-year, while the newly launched "Renzhi·Gege" has surpassed 10 million yuan in revenue within just three months [5]. - The ability of Huaxi Biological to return to a growth trajectory in 2025 through its medical beauty business is under scrutiny [6].

Group 1: Aging Research and ECM - The 13th aging biomarker, "changes in the extracellular matrix (ECM)," has been added to the influential aging classification standards, highlighting its core role in human aging [1] - The decline in ECM viscoelasticity during aging is linked to various health improvements, including reduced cancer incidence and improved muscle function when high molecular weight hyaluronic acid (HA) is introduced [1] - ECM is a dynamic network that includes HA, collagen, and elastin, and its degradation accelerates systemic aging by affecting mitochondrial homeostasis and inflammation [1] Group 2: Role of Hyaluronic Acid - Hyaluronic acid (HA) plays a crucial role in ECM aging, providing structural support for collagen and activating fibroblasts through signaling pathways [2] - The interaction between HA and collagen is essential for ECM function, and a decline in HA leads to impaired collagen synthesis and overall aging [2] - Traditional anti-aging strategies often focus on single components, but a systemic approach that includes high molecular weight HA can restore ECM balance and promote long-term repair [2] Group 3: Company Insights - Huaxi Biological, a leader in the hyaluronic acid sector, has developed a unique polysaccharide research and development platform and holds a significant position in the global sugar biology industry [3] - The company’s product "Runbaiyan.BoBo," a hyaluronic acid sodium solution with lidocaine, has received approval as a Class III medical device, marking a significant advancement in ECM aging intervention research [3] - The approval of this product indicates stricter regulations in the market, raising entry barriers and promoting industry standardization [3]